Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274884 | 0.86 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL25236742 | 0.86 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1540192 | 0.84 | MAOA (0.52) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL554681 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL554680 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL555137 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL4905285 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1540158 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL376741 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL10175130 | 0.81 | MTNR1A (0.58) | MAOAMAOBMTNR1AMTNR1BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | MAOA 3289/4885MAOB 1743/4885MTNR1A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.